Fentanyl in postmortem forensic toxicology

Clinical Toxicology

Volumn 48, Issue 8, 2010, Pages 771-784

  Palmer, Robert B ^a,b,c  

^a Toxicology Associates Denver   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c ROCKY MOUNTAIN POISON AND DRUG CENTER   (United States)

Author keywords

Forensic toxicology; Necrokinetic; Opioid; Overdose; Poisoning; Postmortem; Postmortem redistribution (PMR); Transdermal

Indexed keywords

FENTANYL; FLUCONAZOLE; ITRACONAZOLE; MIDAZOLAM; RITONAVIR; NARCOTIC ANALGESIC AGENT;

ANESTHESIA INDUCTION; AREA UNDER THE CURVE; AUTOPSY; CHRONIC PAIN; CONTINUOUS INFUSION; DEATH; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG TISSUE LEVEL; FORENSIC TOXICOLOGY; HUMAN; NONHUMAN; OUTPATIENT; OUTPATIENT CARE; PAIN; PH; REVIEW; BLOOD; INTRADERMAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ANALGESICS, OPIOID; FENTANYL; FORENSIC TOXICOLOGY; HUMANS; HYDROGEN-ION CONCENTRATION; INJECTIONS, INTRAVENOUS;

EID: 77958548655     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2010.525514     Document Type: Review

References (116)

1. Calis KA, Kohler DR, Corso DM. Transdermally administered fenta-nyl for pain management. Clin Pharm 1992; 11:22-36.
2. Poklis A. Fentanyl: a review for clinical and analytical toxicologists. J Toxicol Clin Toxicol 1995; 33:439-447.
3. Turock MK, Watts DJ, Mude H, Prestosh J, Stoltzfus J. Fentanyllaced heroin: a report from an unexpected place. Am J Emerg Med 2009; 27:237-239.
4. Holley FO, van Steennis C. Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate i.v. and transdermal delivery. Br J Anaesth 1988; 60:608-613.
5. Worsley MH, MacLeod AD, Brodie MJ, Asbury AJ, Clark C. Inhaled fentanyl as a method of analgesia. Anaesthesia 1990; 45:449-451.
6. Kharasch ED, Whittington D, Hoffer C. Influence of hepatic and intes-tinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. Anesthesiology 2004; 101:729-737.
7. Sebel PS, Barrett CW, Kirk CJ, Heykants J. Transdermal absorption of fentanyl and sufentanil in man. Eur J Clin Pharmacol 1987; 32:529-531.
8. Janssen Pharmaceutica Products L. Fentanyl Transdermal System: full prescribing information and patient information. Titusville, NJ: Jans-sen Pharmaceutica Products; 2007. 1-6.
9. Tharp AM, Winecker RE, Winston DC Fatal intravenous fentanyl abuse: four cases involving extraction of fentanyl from transdermal patches. Am J Forensic Med Pathol 2004; 25:178-181.
10. Prodduturi S, Sadrieh N, Wokovich AM, Doub WH, Westenberger BJ, Buhse L. Transdermal delivery of fentanyl from matrix and reservoir systems: effect of heat and compromised skin. J Pharm Sci 2010; 99:2357-2366.
11. Nelson L, Schwaner R. Transdermal fentanyl: pharmacology and Toxicology. J Med Toxicol 2009; 5:230-241.
12. Mylan Pharmaceuticals I. Fentanyl Transdermal System: Full pre-scribing information and patient information. Morgantown, WV: Mylan Pharmaceuticals, Inc.; 2008:1-6.
13. Plezia PM, Kramer TH, Linford J, Hameroff SR. Transdermal fentanyl: pharmacokinetics and preliminary clinical evaluation. Pharmacotherapy 1989; 9:2-9.
14. Varvel JR, Shafer SL, Hwang SS, Coen PA, Stanski DR. Absorption characteristics of transdermally administered fentanyl. Anesthesiology 1989; 70:928-934.
15. Gourlay GK, Kowalski SR, Plummer JL, Cousins MJ, Armstrong PJ. Fentanyl blood concentration-analgesic response relationship in the treatment of postoperative pain. Anesth Analg 1988; 67:329-337.
16. Lehmann KA, Heinrich C, van Heiss R. Balanced anesthesia and patient-controlled postoperative analgesia with fentanyl: minimum effective concentrations, accumulation and acute tolerance. Acta Ana-esthesiol Belg 1988; 39:11-23.
17. Sathyan G, Guo C, Sivakumar K, Gidwani S, Gupta S. Evaluation of the bioequivalence of two transdermal fentanyl systems following sin-gle and repeat applications. Curr Med Res Opin 2005; 21:1961-1968.
18. Prodduturi S, Wokovich AM, Westenberger BJ, Buhse L, Doub WH. In vitro characterization of fentanyl transdermal systems (Abstract #: F-15) FDA Science Forum 2006; 1.
19. Mills PC, Magnusson BM, Cross SE. Investigation of in vitro trans-dermal absorption of fentanyl from patches placed on skin samples obtained from various anatomic regions of dogs. Am J Vet Res 2004; 65:1697-1700.
20. Larsen RH, Nielsen F, Sorensen JA, Nielsen JB. Dermal penetration of fentanyl: inter-and intraindividual variations. Pharmacol Toxicol 2003; 93:244-248.
21. Southwell D, Barry B, Woodford R. Variations in permeability of human skin within and between specimens. Int J Pharmaceut 1984; 18:299-309.
22. Grobosch T, Weniger S, Lampe D. Fentanyl analytics in a case of fatal misuse of transdermal fentanyl. Toxichem Krimtech 2007; 74:59-63.
23. Anonymous. In brief: heat and transdermal fentanyl. Med Lett Drugs Ther 2009; 51:64.
24. Kemp PM, Harty LE. Fentanyl toxicity due to heat related excessive release from a transdermal patch (abstract). Southwest Association of Toxicologists (SAT) Annual Meeting 2001;Dallas, TX.
25. Newshan G. Heat-related toxicity with the fentanyl transdermal patch. J Pain Symptom Manage 1998; 16:277-278.
26. Ashburn MA, Ogden LL, Zhang J, Love G, Basta SV. The pharmaco-kinetics of transdermal fentanyl delivered with and without controlled heat J Pain 2003; 4:291-297.
27. Mather LE. Clinical pharmacokinetics of fentanyl and its newer deriv-atives. Clin Pharmacokinet 1983; 8:422-446.
28. Mylan Pharmaceuticals I. Fentanyl Transdermal System: Full pre-scribing information and patient information. Morgantown, WV: Mylan Pharmaceuticals, Inc.; 2005:1-6.
29. Schneider E, Brune K. Distribution of fentanyl in rats: an autoradio-graphic study. Naunyn Schmiedebergs Arch Pharmacol 1985; 331: 359-363.
30. Waters CM, Avram MJ, Krejcie TC, Henthorn TK. Uptake of fentanyl in pulmonary endothelium. J Pharmacol Exp Ther 1999; 288:157-163.
31. de Barros Duarte L, Dantas Moises EC, Carvalho Cavalli R, et al. Distribution of fentanyl in the placental intervillous space and in the dif-ferent maternal and fetal compartments in term pregnant women. Eur J Clin Pharmacol 2009;
32. Ibrahim AE, Feldman J, Karim A, Kharasch ED. Simultaneous assess-ment of drug interactions with low-and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharma-codynamics of fentanyl and alfentanil. Anesthesiology 2003; 98:853-861.
33. Olkkola KT, Palkama VJ, Neuvonen PJ. Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology 1999; 91:681-685.
34. Hug CCJ, Murphy MR. Tissue redistribution of fentanyl and termina-tion of its effects in rats. Anesthesiology 1981; 55:369-375.
35. Bjorkman S, Wada DR, Stanski DR. Application of physiologic mod-els to predict the influence of changes in body composition and blood flows on the pharmacokinetics of fentanyl and alfentanil in patients. Anesthesiology 1998; 88:657-667.
36. Haberer JP, Schoeffler P, Couderc E, Duvaldestin P. Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. Br J Anaesth 1982; 54:1267-1270.
37. Adams AP, Pybus DA. Delayed respiratory depression after use of fentanyl during anaesthesia. Br Med J 1978; 1:278-279.
38. Caspi J, Klausner JM, Safadi T, Amar R, Rozin RR, Merin G. Delayed respiratory depression following fentanyl anesthesia for cardiac surgery. Crit Care Med 1988; 16:238-240. (Pubitemid 18081903)
39. Klausner JM, Caspi J, Lelcuk S, Khazam A, Marin G, Hechtman HB, Rozin RR. Delayed muscular rigidity and respiratory depression fol-lowing fentanyl anesthesia. Arch Surg 1988; 123:66-67. (Pubitemid 18059412)
40. Christian CM, 2nd, Waller JL, Moldenhauer CC. Postoperative rigid-ity following fentanyl anesthesia. Anesthesiology 1983; 58:275-277.
41. Stoeckel H, Hengstmann JH, Schuttler J. Pharmacokinetics of fentanyl as a possible explanation for recurrence of respiratory depression. Br J Anaesth 1979; 51:741-745.
42. Bjorkman S, Stanski DR, Verotta D, Harashima H. Comparative tissue concentration profiles of fentanyl and alfentanil in humans predicted from tissue/blood partition data obtained in rats. Anesthesiology 1990; 72:865-873.
43. Labroo RB, Paine MF, Thummel KE, Kharasch ED. Fentanyl metabo-lism by human hepatic and intestinal cytochrome P450 3A4: implica-tions for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 1997; 25:1072-1080.
44. Jin M, Gock SB, Jannetto PJ, Jentzen JM, Wong SH. Pharmacoge-nomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. J Anal Toxicol 2005; 29:590-598.
45. Guitton J, Buronfosse T, Desage M, Lepape A, Brazier JL, Beaune P. Possible involvement of multiple cytochrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil. Biochem Pharmacol 1997; 53:1613-1619.
46. Muijsers RB, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001; 61:2289-2307.
47. Feierman DE. The effect of paracetamol (acetaminophen) on fentanyl metabolism in vitro. Acta Anaesthesiol Scand 2000; 44:560-563.
48. Oda Y, Mizutani K, Hase I, Nakamoto T, Hamaoka N, Asada A. Fent-anyl inhibits metabolism of midazolam: competitive inhibition of CYP3A4 in vitro. Br J Anaesth 1999; 82:900-903.
49. Palkama VJ, Neuvonen PJ, Olkkola KT. The CYP 3A4 inhibitor itra-conazole has no effect on the pharmacokinetics of i.v. fentanyl. Br J Anaesth 1998; 81:598-600.
50. Hallberg P, Marten L, Wadelius M. Possible fluconazole-fentanyl interaction-a case report. Eur J Clin Pharmacol 2006; 62:491-492.
51. Hess R, Stiebler G, Herz A. Pharmacokinetics of fentanyl in man and the rabbit Eur J Clin Pharmacol 1972; 4:137-141.
52. McClain DA, Hug CCJ. Intravenous fentanyl kinetics. Clin Pharmacol Ther 1980; 28:106-114.
53. Bower S, Hull CJ. Comparative pharmacokinetics of fentanyl and alfentanil. Br J Anaesth 1982; 54:871-877. (Pubitemid 12042307)
54. Cartwright P, Prys-Roberts C, Gill K, Dye A, Stafford M, Gray A. Ventilatory depression related to plasma fentanyl concentrations during and after anesthesia in humans. Anesth Analg 1983; 62:966-974.
55. Duthie DJ, Rowbotham DJ, Wyld R, Henderson PD, Nimmo WS. Plasma fentanyl concentrations during transdermal delivery of fentanyl to surgical patients. Br J Anaesth 1988; 60:614-618.
56. Garriott JC, Rodriguez R, Di Maio VJ. A death from fentanyl over-dose. J Anal Toxicol 1984; 8:288-289.
57. Chaturvedi AK, Rao NG, Baird JR. A death due to self-administered fentanyl. J Anal Toxicol 1990; 14:385-387.
58. Pare EM, Monforte JR, Gault R, Mirchandani H. A death involving fentanyl. J Anal Toxicol 1987; 11:272-275.
59. Felgate HE. A suicide involving fentanyl. Bull Int Assoc For Tox 1988; 19:32-33.
60. Matejczyk RJ. Fentanyl related overdose. J Anal Toxicol 1988; 12:236-238.
61. Levine B, Goodin JC, Caplan YH. A fentanyl fatality involving mida-zolam (abstract #: 19). Society of Forensic Toxicologists (SOFT) Annual Meeting. 1989;Chicago, IL.
62. Edinboro LE, Poklis A, Trautman D, Lowry S, Backer R, Harvey CM. Fatal fentanyl intoxication following excessive transdermal applica-tion. J Forensic Sci 1997; 42:741-743.
63. Lilleng PK, Mehlum LI, Bachs L, et al. Deaths after intravenous mis-use of transdermal fentanyl. J Forensic Sci 2004; 49:1364-1366.
64. Reeves MD, Ginifer CJ. Fatal intravenous misuse of transdermal fent-anyl. Med J Aust 2002; 177:552-553.
65. Coon TP, Miller M, Kaylor D, Jones-Spangle K. Rectal insertion of fen-tanyl patches: a new route of toxicity. Ann Emerg Med 2005; 46:473.
66. Schneir AB, Offerman SR, Clark RF. Poisoning from the application of a scrotal transdermal fentanyl patch (abstract #38) Clin Toxicol 2001; 39:487-488.
67. Marquardt KA, Tharratt RS. Inhalation abuse of fentanyl patch. J Toxicol Clin Toxicol 1994; 32:75-78.
68. Woodall KL, Martin TL, McLellan BA. Oral abuse of fentanyl patches (Duragesic): seven case reports. J Forensic Sci 2008; 53:222-225.
69. Martin TL, Woodall KL, McLellan BA. Fentanyl-related deaths in Ontario, Canada: toxicological findings and circumstances of death in 112 cases (2002-2004). J Anal Toxicol 2006; 30:603-610.
70. Olson KN, Luckenbill K, Thompson J, Middleton O, Geiselhart R, Mills KM, Kloss J, Apple FS. Postmortem redistribution of fentanyl in blood. Am J Clin Pathol 2010; 133:447-453.
71. Barrueto FJ, Howland MA, Hoffman RS, Nelson LS. The fentanyl tea bag. Vet Hum Toxicol 2004; 46:30-31.
72. Anderson DT, Muto JJ. Duragesic transdermal patch: postmortem tissue distribution of fentanyl in 25 cases. J Anal Toxicol 2000; 24:627-634.
73. Kuhlman JJJ, McCaulley R, Valouch TJ, Behonick GS. Fentanyl use, misuse, and abuse: a summary of 23 postmortem cases. J Anal Toxicol 2003; 27:499-504.
74. Thompson JG, Baker AM, Bracey AH, Seningen J, Kloss JS, Strobl AQ, Apple FS. Fentanyl concentrations in 23 postmortem cases from the hennepin county medical examiner's office. J Forensic Sci 2007; 52:978-981.
75. Baselt RC. Fentanyl. Disposition of Toxic Drugs and Chemicals in Man. 8th ed. Foster City, CA: Biomedical Publications; 2008:616-619.
76. Levine B, Kauffman G, Caplan YH. The determination and distribu-tion of fentanyl in a postmortem case (abstract #: K31). American Academy of Forensic Sciences (AAFS) Annual Meeting. 1987;San Diego, CA.
77. Winek CL, Wahba WW, Winek CL, Jr., Balzer TW. Drug and chemi-cal blood-level data 2001. Forensic Sci Int 2001; 122:107-123.
78. Glidewell RN, Orr WC, Imes N. Acetazolamide as an adjunct to CPAP treatment: a case of complex sleep apnea in a patient on long-acting opioid therapy. J Clin Sleep Med 2009; 5:63-64.
79. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction 1999; 94:961-972.
80. Bailey PL, Pace NL, Ashburn MA, Moll JW, East KA, Stanley TH. Frequent hypoxemia and apnea after sedation with midazolam and fentanyl. Anesthesiology 1990; 73:826-830.
81. Jones GR. Interpretation of postmortem drug levels. In: Karch SB, ed. Postmortem Toxicology of Drugs of Abuse. New York: CRC Press; 2008:113-130.
82. Pelissier-Alicot AL, Gaulier JM, Champsaur P, Marquet P. Mechanisms underlying postmortem redistribution of drugs: a review. J Anal Toxicol 2003; 27:533-544.
83. Shepherd MF, Lake KD, Kamps MA. Postmortem changes and pharmacokinetics: review of the literature and case report. Ann Pharmacother 1992; 26:510-514.
84. Skopp G, Lutz R, Potsch L, Ganssmann B, Klinder K, Schmidt A, Aderjan R, Mattern R. An in vitro experiment for postmortem vascular permeation. The passage of morphine and morphine glucuronides across a vascular wall. J Forensic Sci 1997; 42:486-491.
85. Langford AM, Pounder DJ. Possible markers for postmortem drug redistribution. J Forensic Sci 1997; 42:88-92.
86. Hilberg T, Ripel A, Slordal L, Bjorneboe A, Morland J. The extent of postmortem drug redistribution in a rat model. J Forensic Sci 1999; 44:956-962.
87. Hilberg T, Bugge A, Beylich KM, Morland J, Bjorneboe A. Diffusion as a mechanism of postmortem drug redistribution: an experimental study in rats. Int J Legal Med 1992; 105:87-91.
88. Roy SD, Flynn GL. Solubility behavior of narcotic analgesics in aque-ous media: solubilities and dissociation constants of morphine, fentanyl, and sufentanil. Pharm Res 1989; 6:147-151.
89. Sawyer WR, Steup DR, Martin BS, Forney RB. Cardiac blood pH as a possible indicator of postmortem interval. J Forensic Sci 1988; 33:1439-1444.
90. Gerostamoulos J, Drummer OH. Postmortem redistribution of mor-phine and its metabolites. J Forensic Sci 2000; 45:843-845.
91. Dalpe-Scott M, DeGouffe M, Garbutt D, Drost M. A comparison of drug concentrations in postmortem cardiac and peripheral blood in 320 cases. Can Soc Forensic Sci J 1995; 28:113-121.
92. Luckenbill K, Thompson J, Middleton O, Kloss J, Apple F. Fentanyl postmortem redistribution: preliminary findings regarding the relation-ship among femoral blood and liver and heart tissue concentrations. J Anal Toxicol 2008; 32:639-643.
93. Ferner RE. Post-mortem clinical pharmacology. Br J Clin Pharmacol 2008; 66:430-443.
94. Wu Chen NB, Donoghue ER, Denton JS, Mitchell BR, Ragab K, Mit-tel K, Bloom M. Fentanyl intoxication: Suicide by transdermal patch (abstract #: K19). American Academy of Forensic Sciences (AAFS) annual meeting 1999; Orlando, FL:
95. Wiesbrock UO, Rochholz G, Franzelius C, Schwark T, Grellner W. [Excessive use of fentanyl patches as the only means of suicide]. Arch Kriminol 2008; 222:23-30.
96. Jumbelic MI. Deaths With Transdermal Fentanyl Patches. Am J Forensic Med Pathol 2009; 31:18-21.
97. Liappas IA, Dimopoulos NP, Mellos E, Gitsa OE, Liappas AI, Rabavilas AD. Oral transmucosal abuse of transdermal fentanyl. J Psychopharmacol 2004; 18:277-280.
98. Menahem S, Shvartzman P. High-dose fentanyl patch for cancer pain. J Am Board Fam Pract 2004; 17:388-390.
99. Bleeker CP, Bremer RC, Dongelmans DA, van Dongen RT, Crul BJ. Inefficacy of high-dose transdermal fentanyl in a patient with neuropathic pain, a case report. Eur J Pain 2001; 5:325-329; discussion 329-331.
100. Arvanitis ML, Satonik RC. Transdermal fentanyl abuse and misuse. Am J Emerg Med 2002; 20:58-59.
101. SOFT. SOFT/AAFS Forensic Toxicology Laboratory Guidelines Society of Forensic Toxicologists (SOFT) 2006; 1-24.
102. Hargrove VM, McCutcheon JR. Comparison of drug concentrations taken from clamped and unclamped femoral vessels. J Anal Toxicol 2008; 32:621-625.
103. Hilberg T, Rogde S, Morland J. Postmortem drug redistribution-human cases related to results in experimental animals. J Forensic Sci 1999; 44:3-9.
104. Baselt RC. Methadone. Disposition of Toxic Drugs and Chemicals in Man. 8th ed. Foster City, CA: Biomedical Publications; 2008: 941-945.
105. Caplehorn JR, Drummer OH. Methadone dose and post-mortem blood concentration. Drug Alcohol Rev 2002; 21:329-333.
106. Milroy CM, Forrest AR. Methadone deaths: a toxicological analysis. J Clin Pathol 2000; 53:277-281.
107. Coopman V, Cordonnier J, Pien K, Van Varenbergh D. LC-MS/MS analysis of fentanyl and norfentanyl in a fatality due to application of multiple Durogesic transdermal therapeutic systems. Forensic Sci Int 2007; 169:223-227.
108. Biedrzycki OJ, Bevan D, Lucas S. Fatal overdose due to prescription fentanyl patches in a patient with sickle cell/beta-thalassemia and acute chest syndrome: a case report and review of the literature. Am J Forensic Med Pathol 2009; 30:188-190.
109. Poklis A, Backer R. Urine concentrations of fentanyl and norfentanyl during application of Duragesic transdermal patches. J Anal Toxicol 2004; 28:422-425.
110. Van Nimmen NF, Poels KL, Veulemans HA. Highly sensitive gas chromatographic-mass spectrometric screening method for the determination of picogram levels of fentanyl, sufentanil and alfen-tanil and their major metabolites in urine of opioid exposed workers. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 804:375-387.
111. Moore C, Marinetti L, Coulter C, Crompton K. Analysis of pain man-agement drugs, specifically fentanyl, in hair: application to forensic specimens. Forensic Sci Int 2008; 176:47-50.
112. Oechsler S, Zimmer G, Pedal I, et al. [Has the transdermal patch gone up in smoke? A fatal fentanyl intoxication]. Arch Kriminol 2009; 224:26-35.
113. Lafreniere NM, Watterson JH. Detection of acute fentanyl expo-sure in fresh and decomposed skeletal tissues. Forensic Sci Int 2009; 185:100-106.
114. Kaferstein H, Sticht G. Comparison of nonradioactive microtiter plate enzyme immunoassays for the sensitive detection of fentanyl. Forensic Sci Int 2000; 113:353-357.
115. Thomasy SM, Mama KR, Stanley SD. Comparison of liquid chroma-tography-mass spectrometry and radioimmunoassay for measurement of fentanyl and determination of pharmacokinetics in equine plasma. J Anal Toxicol 2008; 39:754-759.
116. Watts VW, Caplan YH. Evaluation of the Coat-A-Count 125I fent-anyl RIA: comparison of 125I RIA and GC/MS-SIM for quantifica-tion of fentanyl in case urine specimens. J Anal Toxicol 1990; 14:266-272.